Prof. Bart Leroy (Ghent University, Ghent, Belgium) joined touchOPHTHALMOLOGY in an interview to speak about RNA interference therapy and its advantages in treating inherited retinal diseases caused by CEP290 mutations.
‘RNA Interference Therapy for CEP290-IRD’ was presented at EURETINA 2022, 1–4 September 2022
- Could you tell us a little about inherited retinal diseases (IRD) caused by CEP290 mutations and the unmet needs in their treatment? (00:22)
- Could you explain the mechanism of action of RNA interference therapy? (02:20)
- What are the advantages and limitations of this strategy compared with other gene therapies in IRD? (05:48)
- What clinical evidence supports the use of RNA interference therapy? (08:02)
- What questions remain unanswered and what future studies are planned? (12:27)
Disclosures: Bart Leroy is a consultant for and receives grant/research support from ProQR Therapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.
Filmed as a highlight of EURETINA 2022.
